bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Materials and Methods from Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy
Authors: Du Jian , Yan Lei , Torres Raquel , Gong Xueqian , Bian Huimin , Marugán Carlos , Boehnke Karsten , Baquero Carmen , Hui Yu-Hua , Chapman Sonya C. , Yang Yanzhu , Zeng Yi , Bogner Sarah M. , Foreman Robert T. , Capen Andrew , Donoho Gregory P. , Van Horn Robert D. , Barnard Darlene S. , Dempsey Jack A. , Beckmann Richard P. , Marshall Mark S. , Chio Li-Chun , Qian Yuewei , Webster Yue W. , Aggarwal Amit , Chu Shaoyou , Bhattachar Shobha , Stancato Louis F. , Dowless Michele S. , Iversen Phillip W. , Manro Jason R. , Walgren Jennie L. , Halstead Bartley W. , Dieter Matthew Z. , Martinez Ricardo , Bhagwat Shripad V. , Kreklau Emiko L. , Lallena Maria Jose , Ye Xiang S. , Patel Bharvin K.R. , Reinhard Christoph , Plowman Gregory D. , Barda David A. , Henry James R. , Buchanan Sean G. , Campbell Robert M.
Published: April 2023

Supplementary Materials and Methods
Supplementary Table 1, Table 2; Supplementary Figure 1 from ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope
Authors: Phillips Andrew C. , Boghaert Erwin R. , Vaidya Kedar S. , Mitten Michael J. , Norvell Suzanne , Falls Hugh D. , DeVries Peter J. , Cheng Dong , Meulbroek Jonathan A. , Buchanan Fritz G. , McKay Laura M. , Goodwin Neal C. , Reilly Edward B.
Published: April 2023

Table S1: Mouse Strains Used for Xenograft Studies; Table S2: ABT-414 Growth Inhibition of Xenograft Tumors; Figure S1: Efficacy of ABT-414, ABT-806-vcMMAE, and unconjugated MMAE co-dosed with ABT-806 in U87MGde2-7 Tumor-Bearing Mice.
Supplementary Data from Molecular Inhibitor of QSOX1 Suppresses Tumor Growth In Vivo
Authors: Fifield Amber L. , Hanavan Paul D. , Faigel Douglas O. , Sergienko Eduard , Bobkov Andrey , Meurice Nathalie , Petit Joachim L. , Polito Alysia , Caulfield Thomas R. , Castle Erik P. , Copland John A. , Mukhopadhyay Debabrata , Pal Krishnendu , Dutta Shamit K. , Luo Huijun , Ho Thai H. , Lake Douglas F.
Published: April 2023

*Supplementary Figure 1 shows the chemical structure of SBI-183. *Supplementary Figure 2 displays the verification of shRNA KD of QSOX1 by qRT-PCR. *Supplementary Table 1 shows the results from our docking protocols. *Supplementary Figure 3 displays the determination of IC50's by Cell Titer Glo. *Supplementary Table 2 displays cell growth as percentages. *Supplementary Table 3 shows that high dosage with SBI-183 was not toxic to athymic nude mice. *Supplementary Table 4 shows that SBI-183 did not reduce primary tumor growth of MDA-MB-231 in vivo. *Supplementary Figure 4 shows that SBI-183 inhibits metastasis of MDA-MB-231.
Supplementary Methods, Tables and Figures from Antitumor Activity of the IGF-1/IGF-2–Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models
Authors: Weyer-Czernilofsky Ulrike , Hofmann Marco H. , Friedbichler Katrin , Baumgartinger Rosa , Adam Paul J. , Solca Flavio , Kraut Norbert , Nguyen Holly M. , Corey Eva , Liu Gang , Sprenger Cynthia C. , Plymate Stephen R. , Bogenrieder Thomas
Published: April 2023

Supplementary Methods. Supplementary Table S1 shows the dates of mycoplasma testing and STR analysis for each cell line; Supplementary Table S2 shows the primary antibodies used for Western blot or Simple Western{trade mark, serif} analysis, and the TaqMan primer and probe sets used for real-time qPCR; Supplementary Table S3 shows the GSEA results of all C2-canonical pathways with false discovery rate < 0.05; Supplementary Fig. S1 shows protein expression of AR, IGF-1R, and PTEN, and the effect of ENZA and XENT, alone or in combination, on IGF-1R and AKT phosphorylation status in prostate cancer cells; Supplementary Fig. S2 shows analysis of PTEN knockdown by qPCR and Western blot; Supplementary Fig. S3 shows the effect of XENT and ENZA, alone or in combination, on transcript and protein levels of AR-regulated and AR-V7 target genes in VCaP cells; Supplementary Fig. S4 shows the effect of XENT and ENZA, alone or in combination, on caspase 3/7 activity and on total protein levels of apoptotic regulators; Supplementary Fig. S5 shows AR-FL and AR-V7 mRNA and protein expression in LuCaP 96CR PDX; Supplementary Fig. S6 shows the paired end, unstranded RNA-Seq profile matching to the PTEN locus in LuCaP 96CR.
Supplemental Movie 1 from The FOXM1 Inhibitor RCM-1 Decreases Carcinogenesis and Nuclear β-Catenin
Authors: Shukla Samriddhi , Milewski David , Pradhan Arun , Rama Nihar , Rice Kathryn , Le Tien , Flick Matthew J. , Vaz Sara , Zhao Xueheng , Setchell Kenneth D. , Logarinho Elsa , Kalinichenko Vladimir V. , Kalin Tanya V.
Published: April 2023

Supplemental movie 1 shows live imaging to measure the cell cycle and mitotic duration in Vehicle-treated Rd76-9 cells.
Figure S1, Table S1, Table S2 from KLF4 p.A472D Mutation Contributes to Acquired Resistance to Cetuximab in Colorectal Cancer
Authors: Ye Song , Hu Xiaoge , Ni Chao , Jin Weiwei , Xu Yaping , Chang Lianpeng , Zhou Huaixiang , Jiang Jiahong , Yang Liu
Published: April 2023

Figure S1, Table S1, Table S2
Supplementary Figure S3 from Clinicopathological and Functional Significance of RECQL1 Helicase in Sporadic Breast Cancers
Authors: Arora Arvind , Parvathaneni Swetha , Aleskandarany Mohammed A. , Agarwal Devika , Ali Reem , Abdel-Fatah Tarek , Green Andrew R. , Ball Graham R. , Rakha Emad A. , Ellis Ian O. , Sharma Sudha , Madhusudan Srinivasan
Published: April 2023

RECQL1 depletion and ER alpha levels in breast cancer cells
Supplementary Figure S1 from Clinicopathological and Functional Significance of RECQL1 Helicase in Sporadic Breast Cancers
Authors: Arora Arvind , Parvathaneni Swetha , Aleskandarany Mohammed A. , Agarwal Devika , Ali Reem , Abdel-Fatah Tarek , Green Andrew R. , Ball Graham R. , Rakha Emad A. , Ellis Ian O. , Sharma Sudha , Madhusudan Srinivasan
Published: April 2023

RECQL1 expression and survival in ER+ or ER- breast cancers
Supplementary Fig. S2 from Proteoglycans as Target for an Innovative Therapeutic Approach in Chondrosarcoma: Preclinical Proof of Concept
Authors: Peyrode Caroline , Weber Valérie , Voissière Aurélien , Maisonial-Besset Aurélie , Vidal Aurélien , Auzeloux Philippe , Gaumet Vincent , Borel Michèle , Dauplat Marie-Mélanie , Quintana Mercedes , Degoul Françoise , Rédini Françoise , Chezal Jean-Michel , Miot-Noirault Elisabeth
Published: April 2023

Characterization of [3H]-Mel and [3H]-Mel-QA
Figure S5 from Inhibition of Autotaxin with GLPG1690 Increases the Efficacy of Radiotherapy and Chemotherapy in a Mouse Model of Breast Cancer
Authors: Tang Xiaoyun , Wuest Melinda , Benesch Matthew G.K. , Dufour Jennifer , Zhao YuanYuan , Curtis Jonathan M. , Monjardet Alain , Heckmann Bertrand , Murray David , Wuest Frank , Brindley David N.
Published: April 2023

ATX activity in conditioned media of Hs578Bst stromal fibroblasts and patient-matching Hs578T breast cancer cells. Cells were exposed to different doses of g-radiation and ATX activity was measured 24 h after irradiation. n=3 to 5 for each condition. *P<0.05 compared with Hs578T cells.
Figure S4 from Lenalidomide Augments the Antitumor Activities of Eps8 Peptide-Specific Cytotoxic T Lymphocytes against Multiple Myeloma
Authors: Xie Xiaoling , Chen Yiran , Hu Yuxing , He Yanjie , Zhang Honghao , Li Yuhua
Published: April 2023

Reconstitution of human immune components in NCG recipients. High levels of human cell engraftment were found in the peripheral blood, BM and spleen. The engrafted human CD45+ cells included CD3+ T cells. (B) Hematoxylin/eosin staining of spleen and lung sections of human CD45+ humanized mice. Scale bar: 100 μm. These data indicated that a hPBMC-humanized model was successfully established.
Figure S5 from Targeting of BRM Sensitizes BRG1-Mutant Lung Cancer Cell Lines to Radiotherapy
Authors: Zernickel Erika , Sak Ali , Riaz Assad , Klein Diana , Groneberg Michael , Stuschke Martin
Published: April 2023

BRM knock-down increases the number of residual Rad51-foci in BRG1-mutant tumors in an explant model from xenograft tumors
Supplementary Figure S4 from ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine
Authors: Bhagwat Shripad V. , McMillen William T. , Cai Shufen , Zhao Baohui , Whitesell Matthew , Shen Weihua , Kindler Lisa , Flack Robert S. , Wu Wenjuan , Anderson Bryan , Zhai Yan , Yuan Xiu-Juan , Pogue Meghann , Van Horn Robert D. , Rao Xi , McCann Denis , Dropsey Andrew J. , Manro Jason , Walgren Jennie , Yuen Eunice , Rodriguez Michael J. , Plowman Gregory D. , Tiu Ramon V. , Joseph Sajan , Peng Sheng-Bin
Published: April 2023

Effect of LY3214996 on body weight change and calculation of %dT/C in HCT116 xenograft model.
Supplementary Table 1 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
Authors: Miller Rowan E. , Brough Rachel , Bajrami Ilirjana , Williamson Chris T. , McDade Simon , Campbell James , Kigozi Asha , Rafiq Rumana , Pemberton Helen , Natrajan Rachel , Joel Josephine , Astley Holly , Mahoney Claire , Moore Jonathan D. , Torrance Chris , Gordan John D. , Webber James T. , Levin Rebecca S. , Shokat Kevan M. , Bandyopadhyay Sourav , Lord Christopher J. , Ashworth Alan
Published: April 2023

Supplier and catalogue number of compounds included in high-throughput drug screen
Supplementary Figure legends and methods from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
Authors: Miller Rowan E. , Brough Rachel , Bajrami Ilirjana , Williamson Chris T. , McDade Simon , Campbell James , Kigozi Asha , Rafiq Rumana , Pemberton Helen , Natrajan Rachel , Joel Josephine , Astley Holly , Mahoney Claire , Moore Jonathan D. , Torrance Chris , Gordan John D. , Webber James T. , Levin Rebecca S. , Shokat Kevan M. , Bandyopadhyay Sourav , Lord Christopher J. , Ashworth Alan
Published: April 2023

Figure legends for Supplementary figures and supplementary methods
Table S7 from Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer
Authors: Santos Cristina , Azuara Daniel , Garcia-Carbonero Rocio , Alfonso Pilar Garcia , Carrato Alfredo , Elez Mª Elena , Gomez Auxiliadora , Losa Ferran , Montagut Clara , Massuti Bartomeu , Navarro Valenti , Varela Mar , Lopez-Doriga Adriana , Moreno Victor , Valladares Manuel , Manzano Jose Luis , Vieitez Jose Maria , Aranda Enrique , Sanjuan Xavier , Tabernero Josep , Capella Gabriel , Salazar Ramon
Published: April 2023

S7. Progression-free survival and overall survival in the cohort of patients treated with anti-EGFR in first-line (N= 83) and in second line and beyond (N = 99).
Figure S1 from Macrophage Susceptibility to Emactuzumab (RG7155) Treatment
Authors: Pradel Leon P. , Ooi Chia-Huey , Romagnoli Solange , Cannarile Michael A. , Sade Hadassah , Rüttinger Dominik , Ries Carola H.
Published: April 2023

Spatial distribution maps of selected SNPs and CSF-1R structural model
Supplementary Fig.3 from Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor
Authors: Wu Tingyu , Chen Wei , Zhong Yongwang , Hou Xiaodan , Fang Shengyun , Liu Chen-Ying , Wang Guanghui , Yu Tong , Huang Yu-Yang , Ouyang Xuesong , Li Henry Q.X. , Cui Long , Yang Yili
Published: April 2023

Bortezomib induced nuclear export of p53 in SW480 and SW620 cells.
Supplemenatry Figure S7 from PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer
Authors: Jhuraney Ankita , Woods Nicholas T. , Wright Gabriela , Rix Lily , Kinose Fumi , Kroeger Jodi L. , Remily-Wood Elizabeth , Cress W. Douglas , Koomen John M. , Brantley Stephen G. , Gray Jhanelle E. , Haura Eric B. , Rix Uwe , Monteiro Alvaro N.
Published: April 2023

(A) TMA2 WEE1 and PAXIP1 staining, breakdown by KRAS mutation and WEE1/PAXIP1 staining status. (B) TMA3 - WEE1 and PAXIP1 staining.
Figure S2 from Identification and Validation of Compounds Selectively Killing Resistant Cancer: Delineating Cell Line–Specific Effects from P-Glycoprotein–Induced Toxicity
Authors: Füredi András , Tóth Szilárd , Szebényi Kornélia , Pape Veronika F.S. , Türk Dóra , Kucsma Nóra , Cervenak László , Tóvári József , Szakács Gergely
Published: April 2023

Supplementary Figure 2. Treatment of MESSA-Dx5 cells with NSC293766 results in the loss of Pgp (green), while 8OHQ has no effect. Blue: nuclear counterstain. Scale bar is 50 µm
Supplementary Figure S3 from Chromatin Regulators as a Guide for Cancer Treatment Choice
Authors: Gurard-Levin Zachary A. , Wilson Laurence O.W. , Pancaldi Vera , Postel-Vinay Sophie , Sousa Fabricio G. , Reyes Cecile , Marangoni Elisabetta , Gentien David , Valencia Alfonso , Pommier Yves , Cottu Paul , Almouzni Geneviève
Published: April 2023

Comparison of Affymetrix and NanoString gene expression data
Supplemental Table 1 from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology
Authors: Thibault Stephane , Hu Wenyue , Hirakawa Brad , Kalabat Dalia , Franks Tania , Sung Tae , Khoh-Reiter Su , Lu Shuyan , Finkelstein Martin , Jessen Bart , Sacaan Aida
Published: April 2023

Table S1 shows plasma exposure in humans or rats.
Supplementary Table S4 from A Novel Combination Treatment Targeting BCL-XL and MCL1 for KRAS/BRAF-mutated and BCL2L1-amplified Colorectal Cancers
Authors: Cho Sung-Yup , Han Jee Yun , Na Deukchae , Kang Wonyoung , Lee Ahra , Kim Jooyoung , Lee Jieun , Min Seoyeon , Kang Jinjoo , Chae Jeesoo , Kim Jong-Il , Park Hansoo , Lee Won-Suk , Lee Charles
Published: April 2023

Functionally enriched Gene Ontology biological processes in combination treatment of ABT-263 and YM-155 compared to other samples (P<0.05).
Supplementary Table S1 from Oncogenic Receptor Tyrosine Kinases Directly Phosphorylate Focal Adhesion Kinase (FAK) as a Resistance Mechanism to FAK-Kinase Inhibitors
Authors: Marlowe Timothy A. , Lenzo Felicia L. , Figel Sheila A. , Grapes Abigail T. , Cance William G.
Published: April 2023

Statistics for Figure 1 Excel File
Figure S2. Increased MAPK pathway activation upon acquisition of dasatinib-resistance. from The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer
Authors: Beadnell Thomas C. , Mishall Katie M. , Zhou Qiong , Riffert Stephen M. , Wuensch Kelsey E. , Kessler Brittelle E. , Corpuz Maia L. , Jing Xia , Kim Jihye , Wang Guoliang , Tan Aik Choon , Schweppe Rebecca E.
Published: April 2023

A.) Densitometry quantification of ERK 1/2 phosphorylation. Fold changes were calculated based on the control cell lines being normalized to 1. Signals were normalized to α-tubulin. Quantification represents the mean of at least 3 separate experiments for each cell line +/- SEM B.) Western blot analysis after c-Src knockdown using two independent shRNAs (1 & 2) in the BCPAP cell line. Analysis was performed in comparison to a non-transfected (WT) and scrambled control (-). Lysates were probed for c-Src, ppERK1/2, ERK1/2, and α-tubulin. C.) Densitometry quantification of BRAF co-immunoprecipitations after c-Raf pulldown in the control and dasatinib resistant cell lines. Fold Changes are relative to DMSO controls, and densitometry was normalized to CRAF pulldown. D.) Quantification of ERK 1/2 phosphorylation based on western blot analysis for ppERK 1/2 in whole cell lysates following treatment of cells with 100nM dasatinib for 0,2,4,8,24,48, or 46 hours plus a 2 hour challenge (48+2). Fold changes were calculated based on the DMSO (0hr) treatment being normalized to 1. Signals were normalized to α-tubulin or β-actin. Quantification represents the mean of at least 3 separate experiments for each cell line +/- SEM. E.) Cells transfected with the c-Fos-SRE-Luc and pRL-null vectors were assayed for luciferase activity using the Dual Luciferase Reporter Assay System (Promega) after being treated with 100nM dasatinib for 0,2,4,8,24,48, or 46 hours plus a 2 hour challenge (48+2). Signals were normalized to the DMSO (0hr) treatment. Quantification represents the mean of 3 separate experiments +/- SEM.
Figure S1. Enrichment of the Melanoma pathway in the dasatinib-resistant cell lines. from The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer
Authors: Beadnell Thomas C. , Mishall Katie M. , Zhou Qiong , Riffert Stephen M. , Wuensch Kelsey E. , Kessler Brittelle E. , Corpuz Maia L. , Jing Xia , Kim Jihye , Wang Guoliang , Tan Aik Choon , Schweppe Rebecca E.
Published: April 2023

The Kegg pathway Melanoma was enriched (p-value: 0.1465), enriched in the DasRes cell lines. Portrayed are the genes in the melanoma pathway. Highlighted in dark grey are genes that are enriched in the dasatinib-resistant cell lines. Genes enriched include: PIK3R5, E2F3, IGF1R, PIK3CG, PDGFB, FGF7, FGF21, FGF22, BRAF, E2F1, FGF2, FGF14, FGF9, MAPK1, EGFR, PDGFC, FGF1, CCND1, MAP2K1.
Supplementary Figures S1-S9 from N-Arachidonoyl Dopamine Inhibits NRAS Neoplastic Transformation by Suppressing Its Plasma Membrane Translocation
Authors: Wu Min , Huang Jinyan , Zhang Jianming , Benes Cyril , Jiao Bo , Ren Ruibao
Published: April 2023

Supplementary Figure S1: IC50 of PDA and ODA; Supplementary Figure S2: cell number and ATP level comparison after NADA treatment; Supplementary Figure S3: NADA inhibits Ba/F3-N cell proliferation; Supplementary Figure S4: NADA induce cell death could not be rescued by z-VAD-FMK; Supplementary Figure S5: NRAS-transformed cells are more susceptible to NADA induced cell death than KRAS4B-transformed cells; Supplementary Figure S6. Effect of NADA on NRAS signaling in Ba/F3 cells; Supplementary Figure S7: NADA interrupts NRAS plasma membrane localization in a time-dependent manner; Supplementary Figure S8: Effect of NADA on palmitoylation of NRAS and cellular proteins; Supplementary Figure S9: NRAS localization in untreated GFP-NRAS-G12D transformed HeLa cells.
Supplementary Information text S1 from Dissecting Therapeutic Resistance to ERK Inhibition
Authors: Jha Sharda , Morris Erick J. , Hruza Alan , Mansueto My Sam , Schroeder Gottfried K. , Arbanas Jaren , McMasters Daniel , Restaino Clifford R. , Dayananth Priya , Black Stuart , Elsen Nathaniel L. , Mannarino Anthony , Cooper Alan , Fawell Stephen , Zawel Leigh , Jayaraman Lata , Samatar Ahmed A.
Published: April 2023

Theoretical maximum binding capacity of immobilized ligand
Supplementary Information Figure S5 from Dissecting Therapeutic Resistance to ERK Inhibition
Authors: Jha Sharda , Morris Erick J. , Hruza Alan , Mansueto My Sam , Schroeder Gottfried K. , Arbanas Jaren , McMasters Daniel , Restaino Clifford R. , Dayananth Priya , Black Stuart , Elsen Nathaniel L. , Mannarino Anthony , Cooper Alan , Fawell Stephen , Zawel Leigh , Jayaraman Lata , Samatar Ahmed A.
Published: April 2023

Analysis of active ERK2 G169D mutant binding to SCH772984
Supplementary Table 2 from Dual Inhibition of NOX2 and Receptor Tyrosine Kinase by BJ-1301 Enhances Anticancer Therapy Efficacy via Suppression of Autocrine-Stimulatory Factors in Lung Cancer
Authors: Gautam Jaya , Ku Jin-Mo , Regmi Sushil Chandra , Jeong Hyunyoung , Wang Ying , Banskota Suhrid , Park Myo-Hyeon , Nam Tae-gyu , Jeong Byeong-Seon , Kim Jung-Ae
Published: April 2023

The IC50 of BJ-1301, Î±-TOH, and sunitinib with respect to receptor tyrosine kinases
Supplementary Figure Legends from MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2
Authors: Li Peilong , Zhang Xin , Wang Haiyan , Wang Lili , Liu Tong , Du Lutao , Yang Yongmei , Wang Chuanxin
Published: April 2023

Figure legends for supplementary figures
Supplementary Table S2 from Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017
Authors: Uitdehaag Joost C.M. , Kooijman Jeffrey J. , de Roos Jeroen A.D.M. , Prinsen Martine B.W. , Dylus Jelle , Willemsen-Seegers Nicole , Kawase Yusuke , Sawa Masaaki , de Man Jos , van Gerwen Suzanne J.C. , Buijsman Rogier C. , Zaman Guido J.R.
Published: April 2023

Biochemical profiling of kinase inhibitors
Table S1 from Theranostic Radiolabeled Anti-CD20 sdAb for Targeted Radionuclide Therapy of Non-Hodgkin Lymphoma
Authors: Krasniqi Ahmet , D'Huyvetter Matthias , Xavier Catarina , Van der Jeught Kevin , Muyldermans Serge , Van Der Heyden José , Lahoutte Tony , Tavernier Jan , Devoogdt Nick
Published: April 2023

Quantification of in vivo biodistribution of 14 anti-hCD20 sdAbs, radiolabeled with 99mTc, obtained after 1 h p.i., expressed as mean % IA/cm3 {plus minus} SD (n = 3 per sdAb).
Supplementary Table 1 from ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms
Authors: Couts Kasey L. , Bemis Judson , Turner Jacqueline A. , Bagby Stacey M. , Murphy Danielle , Christiansen Jason , Hintzsche Jennifer D. , Le Anh , Pitts Todd M. , Wells Keith , Applegate Allison , Amato Carol , Multani Pratik , Chow-Maneval Edna , Tentler John J. , Shellman Yiqun G. , Rioth Matthew J. , Tan Aik-Choon , Gonzalez Rene , Medina Theresa , Doebele Robert C. , Robinson William A.
Published: April 2023

Primer sequences
Supplementary Table S1 from Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify Kras-Mutant Lung Cancers
Authors: Talwelkar Sarang S. , Nagaraj Ashwini S. , Devlin Jennifer R. , Hemmes Annabrita , Potdar Swapnil , Kiss Elina A. , Saharinen Pipsa , Salmenkivi Kaisa , Mäyränpää Mikko I. , Wennerberg Krister , Verschuren Emmy W.
Published: April 2023

Table_S1
Supplementary Figure S5 from Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor
Authors: Langdon Casey G. , Platt James T. , Means Robert E. , Iyidogan Pinar , Mamillapalli Ramanaiah , Klein Michael , Held Matthew A. , Lee Jong Woo , Koo Ja Seok , Hatzis Christos , Hochster Howard S. , Stern David F.
Published: April 2023

Heatmap of normalized AUC and hierarchically clustered by cell line
Supplementary Figures and legends from Carbonic Anhydrase XII Inhibitors Overcome P-Glycoprotein–Mediated Resistance to Temozolomide in Glioblastoma
Authors: Salaroglio Iris C. , Mujumdar Prashant , Annovazzi Laura , Kopecka Joanna , Mellai Marta , Schiffer Davide , Poulsen Sally-Ann , Riganti Chiara
Published: April 2023

The file contains Supplementary Figure S1-S6: Figure S1 shows Pgp and CAXII expression in different culture conditions; Figure S2 shows the effects of compounds 1-5 on chemotherapeutic drugs cytotoxicity; Figure S3 shows the effects of compound 1 and temozolomide in Pgp KO clones; Figure S4 shows isobologram analysis; Figure S5 shows CAXII-KO clones; Figure S6 shows AC and NS tumor growth with different dosing of compound 1 and temozolomide.
Supplementary Figure S4 from Highly Potent, Anthracycline-based Antibody–Drug Conjugates Generated by Enzymatic, Site-specific Conjugation
Authors: Stefan Nikolas , Gébleux Rémy , Waldmeier Lorenz , Hell Tamara , Escher Marie , Wolter Fabian I. , Grawunder Ulf , Beerli Roger R.
Published: April 2023

Comparison of in vitro cell killing activity of sortase A-conjugated ADCs with cleavable and non-cleavable linkers.
Supplementary Figures from Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation
Authors: Simmons John K. , Michalowski Aleksandra M. , Gamache Benjamin J. , DuBois Wendy , Patel Jyoti , Zhang Ke , Gary Joy , Zhang Shuling , Gaikwad Snehal , Connors Daniel , Watson Nicholas , Leon Elena , Chen Jin-Qiu , Kuehl W. Michael , Lee Maxwell P. , Zingone Adriana , Landgren Ola , Ordentlich Peter , Huang Jing , Mock Beverly A.
Published: April 2023

Figures S1-S7
Supplementary Figure 2 from Targeting Plk1 to Enhance Efficacy of Olaparib in Castration-Resistant Prostate Cancer
Authors: Li Jie , Wang Ruixin , Kong Yifan , Broman Meaghan M. , Carlock Colin , Chen Long , Li Zhiguo , Farah Elia , Ratliff Timothy L. , Liu Xiaoqi
Published: April 2023

a negative control to show that synergistic effect does not exist in BRCA wildtype, p53 wildtype cells.
Supplemental Figure legends from CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma
Authors: Shi Chang-Xin , Kortüm K. Martin , Zhu Yuan Xiao , Bruins Laura A. , Jedlowski Patrick , Votruba Patrick G. , Luo Moulun , Stewart Robert A. , Ahmann Jonathan , Braggio Esteban , Stewart A. Keith
Published: April 2023

Figure legends for Figure S1 and S2
Supplement 2. Next generation sequencing results for first round screen from CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma
Authors: Shi Chang-Xin , Kortüm K. Martin , Zhu Yuan Xiao , Bruins Laura A. , Jedlowski Patrick , Votruba Patrick G. , Luo Moulun , Stewart Robert A. , Ahmann Jonathan , Braggio Esteban , Stewart A. Keith
Published: April 2023

RPMI8226Cas9 cells were infected with the CRISPR library. The infected cells were treated with BTZ at 7nM for seven days (changed medium with 7 nM BTZ at day 2 and day 4). Residual cells surviving BTZ treatment were expanded over 15 days without BTZ treatment and then subjected to DNA sequencing. Experimental screening procedures are illustrated in figure 2A. The top 100 sgRNAs that featured in next generation sequencing of surviving cells following BTZ treatment are listed.
FigureS2 from CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma
Authors: Shi Chang-Xin , Kortüm K. Martin , Zhu Yuan Xiao , Bruins Laura A. , Jedlowski Patrick , Votruba Patrick G. , Luo Moulun , Stewart Robert A. , Ahmann Jonathan , Braggio Esteban , Stewart A. Keith
Published: April 2023

A&B. Cloned KMS11 cells with deleted PSMC6 had no difference for response against dexamethasone and melphalan. C. The 26S proteasome has no significant change in MM cells without PSMC6. D&E. Deficiency of PSMC1 to 5 had similar influence on sensitivity of MM cells against BTZ treatment.
Figure S1, Figure S2, Figure S3 from β-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models
Authors: Ganesh Shanthi , Shui Xue , Craig Kevin P. , Koser Martin L. , Chopda Girish R. , Cyr Wendy A. , Lai Chengjung , Dudek Henryk , Wang Weimin , Brown Bob D. , Abrams Marc T.
Published: April 2023

S1: RNAi mediated dose dependent mRNA silencing in human CRC xenografts. S2: Biodistribution and informal tolerability of DCR-BCAT in wild type mice. S3: Trametinib efficacy in human CRCs.
Supplementary Movie S2 from Aggressive Progression in Glioblastoma Cells through Potentiated Activation of Integrin α5β1 by the Tenascin-C–Derived Peptide TNIIIA2
Authors: Fujita Motomichi , Yamamoto Tetsuya , Iyoda Takuya , Fujisawa Tatsuya , Sasada Manabu , Nagai Reo , Kudo Chikako , Otsuka Kazuki , Kamiya Sadahiro , Kodama Hiroaki , Fukai Fumio
Published: April 2023

Time lapse evaluation of cell scattering (TNIIIA2)
Supplementary Data from Aggressive Progression in Glioblastoma Cells through Potentiated Activation of Integrin α5β1 by the Tenascin-C–Derived Peptide TNIIIA2
Authors: Fujita Motomichi , Yamamoto Tetsuya , Iyoda Takuya , Fujisawa Tatsuya , Sasada Manabu , Nagai Reo , Kudo Chikako , Otsuka Kazuki , Kamiya Sadahiro , Kodama Hiroaki , Fukai Fumio
Published: April 2023

This file shows the supplementary figure (S1-S8).
Figure S6 from Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma
Authors: Panowski Siler H. , Kuo Tracy C. , Zhang Yi , Chen Amy , Geng Tao , Aschenbrenner Laura , Kamperschroer Cris , Pascua Edward , Chen Wei , Delaria Kathy , Farias Santiago , Bateman Marjorie , Dushin Russell G. , Chin Sherman M. , Van Blarcom Thomas J. , Yeung Yik Andy , Lindquist Kevin C. , Chunyk Allison G. , Kuang Bing , Han Bora , Mirsky Michael , Pardo Ingrid , Buetow Bernard , Martin Thomas G. , Wolf Jeffrey L. , Shelton David , Rajpal Arvind , Strop Pavel , Chaparro-Riggers Javier , Sasu Barbra J.
Published: April 2023

T cell dynamics in response to BCMA bispecific and ADCs in cynomolgus monkeys.
Table S2: TRA2A-regulated AS events from TRA2A Promoted Paclitaxel Resistance and Tumor Progression in Triple-Negative Breast Cancers via Regulating Alternative Splicing
Authors: Liu Tieju , Sun Huizhi , Zhu Dongwang , Dong Xueyi , Liu Fang , Liang Xiaohui , Chen Chen , Shao Bing , Wang Meili , Wang Yi , Sun Baocun
Published: April 2023

Table S2: TRA2A-regulated AS events
Figure S3 from The Rolipram–Perillyl Alcohol Conjugate (NEO214) Is A Mediator of Cell Death through the Death Receptor Pathway
Authors: Cho Hee-Yeon , Thein Thu Zan , Wang Weijun , Swenson Stephen D. , Fayngor Rochelle A. , Ou Mengting , Marín-Ramos Nagore I. , Schönthal Axel H. , Hofman Florence M. , Chen Thomas C.
Published: April 2023

Human astrocytes produce TRAIL.
Supplemental Figure 3 from Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer
Authors: Naik Shruthi , Galyon Gina D. , Jenks Nathan J. , Steele Michael B. , Miller Amber C. , Allstadt Sara D. , Suksanpaisan Lukkana , Peng Kah Whye , Federspiel Mark J. , Russell Stephen J. , LeBlanc Amy K.
Published: April 2023

Summary of viral transgene expression as assessed by measurement of human IFN-beta
Supplementary Table S2 from Glibenclamide Targets Sulfonylurea Receptor 1 to Inhibit p70S6K Activity and Upregulate KLF4 Expression to Suppress Non-Small Cell Lung Carcinoma
Authors: Xu Kexin , Sun Geng , Li Min , Chen Hongling , Zhang Zuhao , Qian Xixi , Li Ping , Xu Lin , Huang Wenbin , Wang Xuerong
Published: April 2023

Supplementary Table S2 shows the gene ontology biological process analysis of glibenclamide regulated genes.
Supplemental Figure S1, Supplemental Figure S2, Supplemental Table S1, Supplemental Figure S3, Supplemental Figure S4, Supplemental Figure S5, Supplemental Figure S6 from Improved Therapeutic Window in BRCA-mutant Tumors with Antibody-linked Pyrrolobenzodiazepine Dimers with and without PARP Inhibition
Authors: Zhong Haihong , Chen Cui , Tammali Ravinder , Breen Shannon , Zhang Jing , Fazenbaker Christine , Kennedy Maureen , Conway James , Higgs Brandon W. , Holoweckyj Nicholas , Raja Rajiv , Harper Jay , Pierce Andrew J. , Herbst Ronald , Tice David A.
Published: April 2023

Supplemental Figure S1: Knockdown of BRCA1 or BRCA2 sensitizes Hela cells to PBD payload and PBD-based ADC in vitro. Supplemental Figure S2: Genetic deletion of BRCA1 sensitizes cells to PBD-based ADC. Supplemental Table S1: BRCA mutation(s) in patient-derived xenograft models. Supplemental Figure S3: Mean tumor volume graphs of 23 BRCA-deficient PDX tumors response to PBD-ADC treatment compared to untreated group. Supplemental Figure S4: Mean tumor volume graphs of BRCA wild-type PDX tumors response to PBD-ADC treatment compared to untreated group. Supplemental Figure S5: Representative IHC images of 5T4 staining in PDX models. Supplemental Figure S6: No in vivo efficacy was observed in tumor model DMS-114 that does not express 5T4.
Supplementary Figure S4 from Glibenclamide Targets Sulfonylurea Receptor 1 to Inhibit p70S6K Activity and Upregulate KLF4 Expression to Suppress Non-Small Cell Lung Carcinoma
Authors: Xu Kexin , Sun Geng , Li Min , Chen Hongling , Zhang Zuhao , Qian Xixi , Li Ping , Xu Lin , Huang Wenbin , Wang Xuerong
Published: April 2023

Supplementary Figure S4 shows KATP channels openers inhibited the growth of NSCLCs.
Supplementary Table S1 from TAS4464, A Highly Potent and Selective Inhibitor of NEDD8-Activating Enzyme, Suppresses Neddylation and Shows Antitumor Activity in Diverse Cancer Models
Authors: Yoshimura Chihoko , Muraoka Hiromi , Ochiiwa Hiroaki , Tsuji Shingo , Hashimoto Akihiro , Kazuno Hiromi , Nakagawa Fumio , Komiya Yu , Suzuki Satoshi , Takenaka Toru , Kumazaki Masafumi , Fujita Naoya , Mizutani Takashi , Ohkubo Shuichi
Published: April 2023

Supplementary Table S1. Antiproliferative activity against a panel of cancer cell lines.
Supplementary Materials and Methods from TAS4464, A Highly Potent and Selective Inhibitor of NEDD8-Activating Enzyme, Suppresses Neddylation and Shows Antitumor Activity in Diverse Cancer Models
Authors: Yoshimura Chihoko , Muraoka Hiromi , Ochiiwa Hiroaki , Tsuji Shingo , Hashimoto Akihiro , Kazuno Hiromi , Nakagawa Fumio , Komiya Yu , Suzuki Satoshi , Takenaka Toru , Kumazaki Masafumi , Fujita Naoya , Mizutani Takashi , Ohkubo Shuichi
Published: April 2023

Supplementary materials including cell line, antibodies information and methods including pharmacokinetics and signature score.
Supplementary Data from Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma
Authors: Hashiguchi Taylor , Bruss Nur , Best Scott , Lam Vi , Danilova Olga , Paiva Cody J. , Wolf Joelle , Gilbert Erin W. , Okada Craig Y. , Kaur Prabhjot , Drew Lisa , Cidado Justin , Hurlin Peter , Danilov Alexey V.
Published: April 2023

Supplemental Methods, Table and Figures
Supplementary Table 1 from Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability
Authors: Hingorani Dina V. , Doan Matthew K. , Camargo Maria F. , Aguilera Joseph , Song Seung M. , Pizzo Donald , Scanderbeg Daniel J. , Cohen Ezra E.W. , Lowy Andrew M. , Adams Stephen R. , Advani Sunil J.
Published: April 2023

Statistical analysis of xenograft studies.
Supplementary Table S1 from A Chemosensitivity Study of Colorectal Cancer Using Xenografts of Patient-Derived Tumor-Initiating Cells
Authors: Maekawa Hisatsugu , Miyoshi Hiroyuki , Yamaura Tadayoshi , Itatani Yoshiro , Kawada Kenji , Sakai Yoshiharu , Taketo M. Mark
Published: April 2023

Clinical statuses and success rates for PDXs (P0) and TIC spheroids (in vitro)
Supplementary Figure 1 from Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability
Authors: Hingorani Dina V. , Doan Matthew K. , Camargo Maria F. , Aguilera Joseph , Song Seung M. , Pizzo Donald , Scanderbeg Daniel J. , Cohen Ezra E.W. , Lowy Andrew M. , Adams Stephen R. , Advani Sunil J.
Published: April 2023

Antibody conjugation to drug and Cy5.
Supplementary Table 6 from Expression Levels of Therapeutic Targets as Indicators of Sensitivity to Targeted Therapeutics
Authors: Roy Riti , Winteringham Louise N. , Lassmann Timo , Forrest Alistair R.R.
Published: April 2023

Supplementary Table 6a: Spearman correlation values between drug sensitivity and target expression for 86 drugs common between GDSC and CTRP. Supplementary Table 6b: Correlation matrix comparing gene expression values. There are 558 cell lines and 15,934 genes common between both the datasets. Calculated 558x 558 - Correlation matrix comparing gene expression values for 15,934 genes in one cell line from GDSC compared to 15,934 genes in CTRP. Correlation method used was Spearman. Supplementary Table 6c: Spearman correlation values comparing Area under the curve (AUC) values across common cell lines in the GDSC and CTRP datasets for the 86 drugs common between them. Supplementary Table 6d: List of the cell lines where a better gene expression correlation was observed with a different cell line.
Supplementary Table 1 from Expression Levels of Therapeutic Targets as Indicators of Sensitivity to Targeted Therapeutics
Authors: Roy Riti , Winteringham Louise N. , Lassmann Timo , Forrest Alistair R.R.
Published: April 2023

Supplementary Table 1 shows Spearman correlation values between drug sensitivity and gene expression for 250 drugs studied in the GDSC dataset.
Figure S3 from RAC1b Overexpression Confers Resistance to Chemotherapy Treatment in Colorectal Cancer
Authors: Goka Erik T. , Chaturvedi Pallavi , Lopez Dayrelis T. Mesa , Garza Adriana De La , Lippman Marc E.
Published: April 2023

Figure S3. 1,000 HCT116 Empty Vector and Rac1b overexpressing cells were plated in a 96-well plate and treated with different doses of 5FU for 10 days. On day 10, cell viability was analyzed using the PrestoBlue reagent according to the manufacturers instructions. Data was graphed using GraphPad software and IC50 values were generated using the log(inhibitor) vs. response - variable slope function. Data represents quadruplicates and the error bars represent the 95% confidence intervals.
Figure S2 from RAC1b Overexpression Confers Resistance to Chemotherapy Treatment in Colorectal Cancer
Authors: Goka Erik T. , Chaturvedi Pallavi , Lopez Dayrelis T. Mesa , Garza Adriana De La , Lippman Marc E.
Published: April 2023

Figure S2. (A) Chemical structure of JSH-23. (B) HCT116-EV and HCT116-Rac1b cells stably expressing the NFÎºÎ' reporter was treated with different dose of JSH-23 for 4 hours. The cells were lysed in reporter lysis buffer and NFÎºB reporter activity was measured.
Supplementary Figure 4 from Therapeutic and Prophylactic Antitumor Activity of an Oral Inhibitor of Fucosylation in Spontaneous Mammary Cancers
Authors: Disis Mary L. , Corulli Lauren R. , Gad Ekram A. , Koehnlein Marlese R. , Cecil Denise L. , Senter Peter D. , Gardai Shyra J. , Okeley Nicole M.
Published: April 2023

Effect of 2FF-treatment on (A) Mean {plus minus} SEM tumor cell binding of antibody from TgMMTV-neu mice as detected by FACS analysis using (A) untreated (circle) and 2FF-treated (square) purified serum IgG, or untreated (triangle) and 2FF-treated (inverted triangle) serum (n=5 each), (B) geometric mean of untreated (black, MMC; dark gray, M6) or 2FF-treated (unshaded, MMC; light gray, M6) cell surface fucose using LCA, AAL, and AOL lectins, and (C) in vitro growth of untreated cells (circle, MMC; triangle, M6) or cells pretreated with 2FF (>7 days, square, MMC; inverted triangle, M6) and continuously treated with 2FF during the growth analysis (Mean {plus minus} SEM, n=3 each).
Supplementary Figure S5 from Nonclinical Development of Next-generation Site-specific HER2-targeting Antibody–drug Conjugate (ARX788) for Breast Cancer Treatment
Authors: Nagaraja Shastri Prathap , Zhu Jingjing , Skidmore Lillian , Liang Xuejun , Ji Yanping , Gu Yi , Tian Feng , Yao Sulan , Xia Gang
Published: April 2023

Supplementary Figure S5 illustrates anti-drug antibody (ADA) titers in serum samples from the ARX788 repeat-dose cynomolgus toxicity study. Serum samples were collected pre-dose before the first and fourth ARX788 doses and during the 8-week recovery period. Samples were screened in validated methods for presence of ADA, putative positive samples were confirmed in competition assays, and confirmed positive samples were titrated to determine titer levels which were reported as the reciprocal of the dilution. The titers (at all time points) for animals with at least one confirmed positive ADA sample are shown. Significant treatment-induced ADA responses were observed in Animal 2004 with a very high ADA titer of 320000, while Animals 4505, 4003, and 4506 exhibited ADA titers of 6400, 3200, and 640, respectively. All other animals showed either transient ADA responses or ADA titer levels {less than or equal to}16. In concordance with the ADA titers, animal 2004 showed lower serum concentrations on Day 43 (by ~2-fold) and Day 64 (by ~20-fold or BLQ) when compared to other animals in the group. PK results from animals 4505, 4003, and 4506 were limited because the animals in the group did not receive 3rd and 4th doses because of adverse effects. However, the available sparse exposure results from these animals showed lower serum concentrations by 10 to >100-fold when compared to other animals in the group between Day 36 to Day 120.
Figure S1 from Resistance to Pyrrolobenzodiazepine Dimers Is Associated with SLFN11 Downregulation and Can Be Reversed through Inhibition of ATR
Authors: Mao Shenlan , Chaerkady Raghothama , Yu Wen , D’Angelo Gina , Garcia Andrew , Chen Hong , Barrett Allison M. , Phipps Sandrina , Fleming Ryan , Hess Sonja , Koopmann Jens-Oliver , Dimasi Nazzareno , Wilson Susan , Pugh Kathryn , Cook Kimberly , Masterson Luke A. , Gao Changshou , Wu Herren , Herbst Ronald , Howard Philip W. , Tice David A. , Cobbold Mark , Harper Jay
Published: April 2023

Characterization of 361-PBDr resistant line
Supplementary Tables 1-5 from CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma
Authors: Xu Duo , Liang Shun-Qing , Yang Haitang , Bruggmann Rémy , Berezowska Sabina , Yang Zhang , Marti Thomas Michael , Hall Sean Ralph Robert , Gao Yanyun , Kocher Gregor J. , Schmid Ralph A. , Peng Ren-Wang
Published: April 2023

Supplementary Table S1. Human kinome sgRNA library used in this study. Supplementary Table S2. PCR primers used in this study. Supplementary Table S3. NGS data of sgRNAs in chemotherapy- and vehicle-treated MESO-1 cells. Supplementary Table S4. Kinase candidates scored in negative selection CRISPR screening. Supplementary Table S5. Sequences of WEE1-specific sgRNAs and negative control sgRNAs.
Supplementary Data from Tankyrase Inhibitors Target Colorectal Cancer Stem Cells via AXIN-Dependent Downregulation of c-KIT Tyrosine Kinase
Authors: Jang Myung-Kyu , Mashima Tetsuo , Seimiya Hiroyuki
Published: April 2023

Supplementary Material and Methods, Supplementary References, Supplementary Figure Legends
Figures S1-S6, model files from Antibody Co-Administration Can Improve Systemic and Local Distribution of Antibody–Drug Conjugates to Increase In Vivo Efficacy
Authors: Ponte Jose F. , Lanieri Leanne , Khera Eshita , Laleau Rassol , Ab Olga , Espelin Christopher , Kohli Neeraj , Matin Bahar , Setiady Yulius , Miller Michael L. , Keating Thomas A. , Chari Ravi , Pinkas Jan , Gregory Richard , Thurber Greg M.
Published: April 2023

Supplementary figures and data
Supplementary Figure from AZD4625 is a Potent and Selective Inhibitor of KRASG12C
Authors: Chakraborty Atanu , Hanson Lyndsey , Robinson David , Lewis Hilary , Bickerton Sue , Davies Michael , Polanski Radoslaw , Whiteley Rebecca , Koers Alex , Atkinson James , Baker Tamara , del Barco Barrantes Ivan , Ciotta Giovanni , Kettle Jason G. , Magiera Lukasz , Martins Carla P. , Peter Alison , Wigmore Eleanor , Underwood Zoe , Cosulich Sabina , Niedbala Michael , Ross Sarah
Published: April 2023

Supplementary Figure from AZD4625 is a Potent and Selective Inhibitor of KRASG12C
Figure S4 from IGF1R Inhibition Enhances the Therapeutic Effects of Gq/11 Inhibition in Metastatic Uveal Melanoma Progression
Authors: Lapadula Dominic , Lam Bao , Terai Mizue , Sugase Takahito , Tanaka Ryota , Farias Eduardo , Kadamb Rama , Lopez-Anton Melisa , Heine Christian C. , Modasia Bhavik , Aguirre-Ghiso Julio A. , Aplin Andrew E. , Sato Takami , Benovic Jeffrey L.
Published: April 2023

Figure S4: Synergy plots of OCM3 (A), OMM1.3 (B), and UM001 (C) cells treated with YM and PPP or BYL719. Left panels show relative cell number as a percent of untreated control cells (100%) and the right panels show the corresponding Loewe synergy plots created using Combenefit software.
Supplementary Table S1, S2, S4, S5 from Emerging Developments in ETS-Positive Prostate Cancer Therapy
Authors: Bowling Gartrell C. , Rands Mitchell G. , Dobi Albert , Eldhose Binil
Published: April 2023

Supplementary Tables S1-S2 and S4-S5
Supplementary Data from First-in-Class Small Molecule to Inhibit CYP11A1 and Steroid Hormone Biosynthesis
Authors: Karimaa Mari , Riikonen Reetta , Kettunen Henna , Taavitsainen Päivi , Ramela Meri , Chrusciel Marcin , Karlsson Stefan , Rummakko Petteri , Simola Outi , Wohlfahrt Gerd , Hakulinen Pasi , Vuorela Annamari , Joensuu Heikki , Utriainen Tapio , Fizazi Karim , Oksala Riikka
Published: April 2023

Supplementary Data from First-in-Class Small Molecule to Inhibit CYP11A1 and Steroid Hormone Biosynthesis
Supplementary Data from Venadaparib Is a Novel and Selective PARP Inhibitor with Improved Physicochemical Properties, Efficacy, and Safety
Authors: Lee Myongjae , Je In-Gyu , Kim Jeong Eun , Yoo Yeongran , Lim Jong-Ha , Jang Eunhye , Lee Yoonsuk , Song Dong Keun , Moon An-Na , Kim Jeong-Ah , Jeong Jinah , Park Joon-Tae , Lee Jung Woo , Yang Ji-Hoon , Hong Chang-Hee , Park Sun-Young , Park Young-Whan , Baek Nam Seok , Lee Sungsook , Ha Kyoung Soo , Choi SungKu , Lee Won Sik
Published: April 2023

Supplementary Table 1, Supplementary Table 2, Supplementary Figure 1
Supplementary Data from Redundant Signaling as the Predominant Mechanism for Resistance to Antibodies Targeting the Type-I Insulin-Like Growth Factor Receptor in Cells Derived from Childhood Sarcoma
Authors: Shackleford Terry J. , Hariharan Seethalakshmi , Vaseva Angelina V. , Alagoa Karina , Espinoza Maricruz , Bid Hemant K. , Li Fuyang , Zhong Haihong , Phelps Doris A. , Roberts Ryan D. , Cam Hakan , London Cheryl A. , Guttridge Denis C. , Chen Yidong , Rao Manjeet , Shiio Yuzuru , Houghton Peter J.
Published: April 2023

Supplemental data
Supplementary Materials and Methods from Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti–PD-1 Antibody
Authors: Niwa Yuki , Adachi Keito , Tabata Kimiyo , Ishida Ryoga , Hotta Koichiro , Ishida Tomomi , Mano Yuji , Ozawa Yoichi , Minoshima Yukinori , Funahashi Yasuhiro , Semba Taro
Published: April 2023

Supplementary Materials and Methods not included in the main manuscript
Data from Ceramide Nanoliposomes as a MLKL-Dependent, Necroptosis-Inducing, Chemotherapeutic Reagent in Ovarian Cancer
Authors: Zhang Xuewei , Kitatani Kazuyuki , Toyoshima Masafumi , Ishibashi Masumi , Usui Toshinori , Minato Junko , Egiz Mahy , Shigeta Shogo , Fox Todd , Deering Tye , Kester Mark , Yaegashi Nobuo
Published: April 2023

Abstract
Ceramides are bioactive lipids that mediate cell death in cancer cells, and ceramide-based therapy is now being tested in dose-escalating phase I clinical trials as a cancer treatment. Multiple nanoscale delivery systems for ceramide have been proposed to overcome the inherent toxicities, poor pharmacokinetics, and difficult biophysics associated with ceramide. Using the ceramide nanoliposomes (CNL), we now investigate the therapeutic efficacy and signaling mechanisms of this nanoscale delivery platform in refractory ovarian cancer. Treatment of ovarian cancer cells with CNL decreased the number of living cells through necroptosis but not apoptosis. Mechanistically, dying SKOV3 ovarian cancer cells exhibit activation of pseudokinase mixed lineage kinase domain-like (MLKL) as evidenced by oligomerization and relocalization to the blebbing membranes, showing necroptotic characteristics. Knockdown of MLKL, but not its upstream protein kinases such as receptor-interacting protein kinases, with siRNA significantly abolished CNL-induced cell death. Monomeric MLKL protein expression inversely correlated with the IC50 values of CNL in distinct ovarian cancer cell lines, suggesting MLKL as a possible determinant for CNL-induced cell death. Finally, systemic CNL administration suppressed metastatic growth in an ovarian cancer cell xenograft model. Taken together, these results suggest that MLKL is a novel pronecroptotic target for ceramide in ovarian cancer models. Mol Cancer Ther; 17(1); 50–59. ©2017 AACR.